Takeda Oncology
Vanessa Stache possesses extensive experience in the field of oncology and medical research. Currently serving as the EUCAN Medical Head Oncology - Heme at Takeda Oncology since June 2017, Vanessa has held multiple roles including Medical Director and Interim Global Medical Communications Lead for Lymphoma. Prior experience includes a postdoctoral scientist position at the Max Delbrück Center, where doctoral research was conducted, as well as research trainee roles at institutions such as the Karolinska Institutet and Leiden University Medical Center, focusing on cancer and immunology. Vanessa holds a Ph.D. in Tumor Immunology from Freie Universität Berlin, a Master of Science in Biomedicine from Karolinska Institutet, and a Bachelor of Science in Molecular Biotechnology from Heidelberg University.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.